



Title	Induced expression of Toll-like receptor 9 in peritubular capillary endothelium correlates with the progression of tubulointerstitial lesions in autoimmune disease-prone mice
Author(s)	Masum, M. A.; Ichii, O.; ELewa, Y. H. A.; Kon, Y.
Citation	Lupus, 28(3), 324-333 https://doi.org/10.1177/0961203319828518
Issue Date	2019-03
Doc URL	http://hdl.handle.net/2115/75181
Rights	M.A. Masum, O. Ichii, Y.H.A. ELewa, and Y. Kon, Induced expression of Toll-like receptor 9 in peritubular capillary endothelium correlates with the progression of tubulointerstitial lesions in autoimmune disease-prone mice, Lupus 28(3) pp. 324-333. Copyright © 2019 M.A. Masum, O. Ichii, Y.H.A. ELewa, and Y. Kon. DOI: 10.1177/0961203319828518.
Type	article (author version)
File Information	Manuscript_Figure.pdf



[Instructions for use](#)

1 **Title page**

2 **Induced expression of Toll-like receptor 9 in peritubular capillary endothelium**
3 **correlates with the progression of tubulointerstitial lesions in autoimmune disease-**
4 **prone mice**

5 Md. Abdul Masum^{1,2}, Osamu Ichii^{1,*}, Yaser Hosny Ali ELewa^{1,3}, and Yasuhiro Kon¹

6 ¹Laboratory of Anatomy, Department of Basic Veterinary Sciences, Faculty of Veterinary
7 Medicine, Hokkaido University, Sapporo, Japan

8 ²Department of Anatomy, Histology and Physiology, Faculty of Animal Science and
9 Veterinary Medicine, Sher-e-Bangla Agricultural University, Dhaka, Bangladesh

10 ³Department of Histology, Faculty of Veterinary Medicine, Zagazig University, Zagazig,
11 Egypt

12 ***Corresponding Author:**

13 Dr. Osamu Ichii,

14 Laboratory of Anatomy, Department of Basic Veterinary Sciences, Faculty of Veterinary
15 Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo 060-0818, Japan

16 Email: ichi-o@vetmed.hokudai.ac.jp

17 Tel: +81-11-706-5189, Fax: +81-11-706-5189

18

19 **Abstract**

20 **Background:** Toll-like receptor (Tlr) 9 is capable of recognizing exogenous and/or
21 endogenous nucleic acids and plays a crucial role in innate and adaptive immunity.
22 Recently, we showed that Tlr9 is overexpressed in podocytes, a component of the blood-
23 urine barrier (BUB), in glomeruli of autoimmune glomerulonephritis (AGN) model mice.
24 This study investigated the activation of peritubular capillary (PTC) endothelial cells
25 (ECs), a component of the BUB in the tubulointerstitium, through overexpressing Tlr9,
26 and the subsequent development of tubulointerstitial lesions (TILs) in AGN model mice.

27 **Methods:** Lupus-prone BXSB/MpJ-Yaa (Yaa) and BXSB/MpJ (BXSB) mice were used
28 as an AGN model and control, respectively. In addition to histopathological and
29 ultrastructural techniques, protein and mRNA levels were also evaluated. The relationship
30 between Tlr9 and TIL indices was analyzed by statistical correlation analysis.

31 **Results:** Yaa mice developed TILs and showed strong Tlr9 mRNA expression in PTC
32 ECs at 24 weeks (wks) of age. However, BXSB mice showed no TIL but faint expression
33 of Tlr9 mRNA at 8 and 24 wks of age. Tlr9 protein localization on PTC was almost absent
34 in BXSB mice at both ages but intense expression was found in Yaa mice only at 24 wks
35 of age. Relative mRNA expression of *Tlr9* and its putative downstream cytokines,
36 including interleukin 1 beta (*Il1b*), *Il6*, interferon gamma (*Ifng*), and tumor necrosis factor
37 alpha (*Tnf*) was markedly increased in isolated tubulointerstitium from Yaa mice at 24
38 wks of age. Furthermore, electron microscopy examination revealed PTC injury and TIL
39 in Yaa mice at 24 wks. The expression level of *Tlr9* in the tubulointerstitium was

40 correlated with inflammatory cells in TILs, injured PTC, *Ilb* and *Tnf* expression, and
41 damaged tubules ($P < 0.05$ and 0.01).

42 **Conclusion:** Induced expression of *Tlr9* in ECs correlates with PTC injury and the
43 development of TILs in lupus-prone AGN model mice.

44 **Keywords**

45 Toll-like receptor 9, peritubular capillary, tubulointerstitial lesions, autoimmune
46 glomerulonephritis, BXSB/MpJ-Yaa mice.

47 **Running title:** Tlr9 in PTC correlates tubulointerstitial lesions.

48 **Introduction**

49 Chronic kidney disease (CKD) affects 22% of human adults in Japan, and 10–
50 13% of the global population (1, 2). Most forms of CKD progress to either end-stage
51 glomerulosclerosis or tubulointerstitial fibrosis (3). Therefore, CKD is a serious public
52 health problem throughout the world, as it is associated with end-stage renal disease
53 (ESRD), cardiovascular complications, and requires dialysis (4).

54 Though a variety of conditions, including infiltration of B-, T-cells, and
55 macrophages, can lead to CKD in human and mice, the final common pathway of renal
56 damage involves interstitial fibrosis, injury, and/or loss of renal tubules and peritubular
57 capillaries (PTCs) (2, 5).

58 PTCs in the kidney are essential for regulating renal function and hemodynamics
59 (6). PTC endothelial cells (ECs) also play a crucial role in expressing specific chemokines
60 that control T-cell and monocyte recruitment during inflammation in experimental
61 animals (7, 8). Importantly, ECs are being gradually recognized as active participants in
62 the host's innate immune response to infection and injury. The engagement of endothelial
63 innate immune receptors with host-derived agonists upregulates the expression of specific
64 cytokines and chemokines, and increases the binding of neutrophils to the endothelium
65 (9). ECs have been shown to express Toll-like receptors (TLRs) that are activated in
66 response to stimuli within the bloodstream, including pathogens and damage signals.

67 Inappropriate endothelial activation through Tlrs contributes to tissue damage during
68 autoimmune and inflammatory diseases in human and murine disease models (10).

69 Tlrs act as sentinel receptors for the mammalian innate immune system and
70 various studies have shown that Tlrs are expressed in intrinsic renal cells (11, 12).
71 Particularly, *Tlr5* and *Tlr11* are expressed in tubular epithelial cells, and Tlrs also play an
72 important role in urinary tract infections in mice (13, 14). The activation of different
73 members of the Tlr family in tubular epithelial cells also contributes to the progression of
74 kidney ischemia-reperfusion injury and subsequent renal fibrosis in human and mice (15).

75 However, among the members of Tlr family, Tlr9 shows the most variability both
76 in expression and its role in the development of kidney diseases. A previous study showed
77 Tlr9 expression in the tubulointerstitium and glomerulus of human patients with renal
78 disease, but only in the tubulointerstitium of normal kidney (16). Machida *et al.*, showed
79 that *Tlr9* is expressed on the podocytes of children with active lupus nephritis whereas
80 *Tlr9* expression was also found in the glomerular capillary endothelium of patients with
81 bacterial CpG-DNA-induced glomerulonephritis (17, 18). Therefore, *Tlr9* expression is
82 not restricted only to antigen-presenting cells but also to murine endothelial cells (19, 20),
83 human dermal microvascular endothelium (21), podocytes (17), and tubulointerstitium
84 (13, 14), and it plays a crucial role in infectious and autoimmune responses. However, the
85 role of Tlr9 in the development of tubulointerstitial lesions (TILs) has remained unclear.

86 Lupus-prone BXSB/MpJ-Yaa (Yaa) mice are generally used as the animal model
87 of autoimmune glomerulonephritis (AGN). Importantly, male Yaa mice show more
88 severe glomerular lesions (GLs) than females because of a mutation called the Y-linked
89 autoimmune acceleration (Yaa) (22, 23). The Yaa locus contains approximately 19
90 protein-coding genes including *Tlr7* and *Tlr8* (22, 23). We also demonstrated that
91 overexpression of *Tlr8* on the Yaa locus and *Tlr9* on the autosome were observed in
92 podocytes, and their expression correlates with the progression of GL of AGN in Yaa
93 mice (24, 25). Further, our previous studies have shown a close relationship with the
94 number of glomerular capillaries and severity of GLs in Yaa mice (5). Importantly, these
95 mice also developed TILs at a later stage. However, the mechanism of TIL development,
96 especially the pathological correlations with Tlr expression, has not been fully elucidated
97 yet.

98 In this study, we showed that *Tlr9* was expressed in injured PTCs of Yaa mice at
99 24 weeks (wks) of age. Moreover, *Tlr9* expression was correlated with TILs, indicating
100 that de novo expression of *Tlr9* was related with PTC injury and subsequent development
101 of TILs in AGN.

102 **Materials and Methods**

103 *Ethical statements and maintenance of experimental animals*

104 All experiments using mice were approved by the Institutional Animal Care and
105 Use Committee of the Faculty of Veterinary Medicine, Hokkaido University (approval
106 No. 13-0032, 16-0124). The authors adhered to the “Guide for the Care and Use of
107 Laboratory Animals of Hokkaido University, Faculty of Veterinary Medicine,” approved
108 by the Association for Assessment and Accreditation of Laboratory Animal Care
109 International throughout the experiments. Six-week-old male BXSB/MpJ (BXSB), Yaa,
110 MRL/MpJ (MRL), and MRL/MpJ-lpr (lpr) mice were purchased from Japan SLC Inc.
111 (Hamamatsu, Japan) and maintained under specific pathogen-free conditions. Twenty-
112 four-week-old Yaa and lpr mice were designated as the AGN model.

113 *Sample collection and preparation*

114 Mice were anesthetized with a mixture of 0.3 mg/kg medetomidine (Kyoritsu
115 Seiyaku, Tokyo, Japan), 5 mg/kg butorphanol (Meiji Seika Pharma, Tokyo, Japan), and
116 4 mg/kg midazolam (Astellas Pharma, Tokyo, Japan). The kidneys were cut into small
117 slices and fixed in 10% neutral buffered formalin (NBF), 4% paraformaldehyde (PFA),
118 or 2.5% glutaraldehyde (GTA) in 0.1 M phosphate buffer (PB) for routine
119 histopathological analysis, immunostaining, and electron microscopy analysis,
120 respectively. Kidney slices were fixed with 4% PFA for 2 hours followed by treatment
121 with 30% sucrose and were then snap frozen in optimum cutting medium. To visualize

122 the vascular structures, the perfusion of Microfil (Flow Tech, Inc. Massachusetts, USA)
123 throughout mouse hearts was performed according to our previously described methods
124 (5).

125 *Histopathological examination*

126 The tissue sections were stained with periodic acid Schiff-hematoxylin (PAS-H)
127 for histopathological analysis. Immunodetection of target cell markers was performed
128 using kidney specimens fixed with PFA; details are listed in Supplementary Table 1.
129 Briefly, deparaffinization and antigen retrieval was followed by submerging tissue
130 sections in methanol containing 3% H₂O₂ for 20 min at room temperature and blocked
131 with normal goat or donkey serum. Sections were incubated with primary antibody
132 overnight at 4°C followed by incubation with the respective secondary antibodies at room
133 temperature for 30 min: Alexa Fluor 546-labeled donkey anti-mouse IgG (Life
134 Technologies, Yokohama, Japan) or Alexa Fluor 488-labeled donkey anti-rabbit IgG
135 (Life Technologies, Yokohama, Japan). The sections were examined under an All-in-One
136 Fluorescence Microscope BZ-X710 (Keyence, Osaka, Japan).

137 For immunohistochemistry, the sections were incubated with the appropriate
138 biotinylated secondary antibody for 30 min, then with streptavidin-horseradish
139 peroxidase (SABPO kit; Nichirei, Tokyo, Japan) for another 30 min, followed by
140 incubation with 3,3-diaminobenzidine tetrahydrochloride-H₂O₂ solution. Finally, the

141 sections were counterstained with hematoxylin, dehydrated in an ascending series of
142 alcohol solutions, and cleared with xylene.

143 ***In situ hybridization***

144 A formalin-fixed paraffin-embedded RNAscope 2.5 assay was used for *in situ*
145 hybridization in the tubulointerstitium. NBF-fixed paraffin-embedded kidney specimens
146 were sliced into 5 µm-thick sections, air-dried overnight, and then baked in an oven for 1
147 h at 60°C. All procedures for *in situ* hybridization were performed according to the
148 manufacturer's instructions for the RNAscope 2.5 HD Reagent Kit-RED (Advanced Cell
149 Diagnostics, Inc., Hayward, CA, USA). RNAscope Target Probe-Mm-Tlr9, Mouse (Cat.
150 No. 468281; Advanced Cell Diagnostics, Inc., Hayward, CA, USA), RNAscope positive
151 control probe-Mm-Polr2a (Cat. No. 312471; Advanced Cell Diagnostics, Inc., Hayward,
152 CA, USA), and RNAscope negative control probe-DapB (Cat. No. 310043; Advanced
153 Cell Diagnostics, Inc., Hayward, CA, USA) was used according to the manufacturer's
154 instructions for *in situ* hybridization.

155 ***Scanning electron microscopy (SEM) and modified SEM (mSEM)***

156 For routine SEM, slices of GTA-fixed kidney were treated with tannic acid and
157 post-fixed with 1% osmium tetroxide (OsO₄). The specimens were dehydrated and dried
158 using an HCP-2 critical point dryer (Hitachi, Tokyo, Japan). The specimens were sputter-
159 coated for 60 s with a Hitachi E-1030 ion sputter coater (Hitachi, Tokyo, Japan). Kidney
160 sections were examined using an S-4100 SEM with an accelerating voltage of 10 kV. We

161 also used our previously described mSEM technique to examine the ultrastructure of the
162 tubulointerstitium (26).

163 ***Histoplanimetry***

164 Digital images randomly selected over 30 glomeruli or 30 tubulointerstitial areas
165 from each mouse were acquired at high magnification (400×) using a BZ-X710
166 fluorescence microscope (Keyence). The number of B220⁺ B-cells, CD3⁺ T-cells, and
167 Iba1⁺ macrophages observed in the digital images of glomeruli were counted manually.

168 In addition to inflammatory cells, IL-1F6/IL-36⁺ tubules were detected in the
169 tubulointerstitium, as its immunoexpression signifies renal tubule damage which is also
170 correlated with TILs and injured capillaries (5, 27). The numbers of B220⁺ B-cells, CD3⁺
171 T-cells, Iba1⁺ macrophages, CD31⁺ PTCs, Tlr9⁺ PTCs, and IL-1F6/IL-36α⁺ damaged
172 tubules in the digital images of the tubulointerstitium were assessed using a BZ-X
173 Analyzer (Keyence). One hundred PTCs were selected randomly from each mouse using
174 images obtained from modified scanning electron microscopy (mSEM). Among these,
175 PTCs showing EC thickening with loss of fenestration as well as irregular and narrow
176 capillary lumina were considered injured PTCs.

177 ***Laser microdissection (LMD), reverse transcription, and real-time PCR***

178 Frozen sections were cut at 5-μm thickness and stained with toluidine blue. First,
179 all glomeruli were removed from a kidney section by LMD using a MicroBeam Rel.4.2
180 (Carl Zeiss; Oberkochen, Germany). Whole kidney sections lacking glomeruli were

181 collected manually for further analysis from each mouse. Total RNA from dissected
182 samples was isolated using a miRNeasy Micro Kit (Qiagen). Complementary DNA
183 (cDNA) was synthesized from total RNA from dissected tubulointerstitium by reverse
184 transcription by using ReverTra Ace qPCR RT Master Mix with gDNA Remover
185 (Toyobo, Osaka, Japan). cDNA was used in real-time PCR with THUNDERBIRD SYBR
186 qPCR mix (Toyobo) and a CFX Connect Real-Time PCR Detection System (Bio-Rad
187 Laboratories, Inc., Tokyo, Japan). Gene expression in the tubulointerstitium was
188 normalized to the expression of β -actin (*Actb*). The primer pairs are shown in
189 Supplementary Table 2.

190 ***Statistical analysis***

191 The results were expressed as the mean \pm standard error. The results were
192 statistically analyzed using a nonparametric Mann-Whitney U-test ($P < 0.05$). The
193 Kruskal-Wallis test was used to compare three or more populations, and multiple
194 comparisons were performed using Scheffe's method when significant differences were
195 observed ($P < 0.05$). The correlation was analyzed using Spearman's rank correlation test
196 ($P < 0.05$).

197

198 **Results**

199 *GLs and TILs in AGN model mice*

200 Renal histopathology was examined in kidney sections from Yaa mice and their
201 respective control BXSB mice at 8 and 24 wks of age (Fig. 1A-D). In control BXSB mice,
202 no GLs or TILs were found at either age examined (Fig. 1A and C). However, Yaa mice
203 showed no GLs and TILs at 8 wks of age but lesions were clearly found at 24 wks of age
204 characterized by glomerular hypertrophy, increase in glomerular cell number, dilatation
205 of tubules, presence of urinary cast in tubules, and infiltrating cells in tubulointerstitial
206 spaces (Fig. 1B and D). Higher numbers of B220⁺ B-cells, CD3⁺ T-cells, and Iba1⁺
207 macrophages were found in GLs and TILs of Yaa mice at 24 wks of age compared to
208 those of Yaa mice at 8 wks of age and BXSB mice at both ages examined (Fig. 1E and
209 F). These results indicate that Yaa mice developed GLs as well as TILs at 24 wks of age.

210 *Normal distribution of PTCs in AGN model mice*

211 Our previous study showed that number of PTCs decreased in a mouse model of
212 TIL by unilateral ureter obstruction and their number related with TIL severity (5). As
213 AGN model mice clearly showed TILs at 24 wks of age in the present study, we examined
214 the distribution of PTCs at this age and found a normal distribution of CD31⁺ PTCs
215 (Supplementary Fig. 1). Further, the number of CD31⁺ PTCs tended to be decreased in
216 Yaa mice compared with BXSB mice, but no significant difference was observed
217 (Supplementary Fig. 1). We also examined the distribution of PTCs in Microfil-perfused

218 kidney sections, and there was no significant difference between BXSB and Yaa mice
219 (Supplementary Fig. 1).

220 ***mRNA expression and protein localization of Tlr9 in PTCs of AGN model mice***

221 For *in situ* hybridization, no signals for *Tlr9* mRNA were detected in the
222 tubulointerstitium of BXSB or Yaa mice at 8 wks of age (Fig. 2A and B). A slight number
223 of signals for *Tlr9* mRNA was detected in the proximal tubules and PTCs of BXSB mice
224 at 24 wks of age (Fig. 2C). However, strong signals for *Tlr9* mRNA were detected in
225 PTCs of Yaa mice at 24 wks of age (Fig. 2D). As also found in our previous study (25),
226 podocytes exhibited *Tlr9* expression (Supplementary Fig. 2). There was no or scant Tlr9
227 protein localization in PTCs of BXSB mice at both ages and Yaa mice at 8 wks of age
228 (Fig. 2E-G). However, Tlr9 protein was abundantly localized in the cytoplasm of PTCs
229 of Yaa mice at 24 wks of age (Fig. 2H). Tlr9-positive reactions were also detected in the
230 podocytes of Yaa mice at 24 wks of age (Supplementary Fig. 2), as shown in our previous
231 study (25). To examine the effect of *Yaa* mutation on Tlr9 expression in PTCs of Yaa
232 mice, Tlr9 protein localization was also examined in another AGN model, *lpr* mice.
233 Similar to the results in BXSB and Yaa mice, the respective control MRL showed no Tlr9
234 protein localization but intense reaction was found in PTCs of kidneys from *lpr* mice
235 (Supplementary Fig. 3). Tlr9 immunoreaction was also confirmed in the spleens of 24
236 week-old Yaa mice (Supplementary Fig. 3). The percentage of Tlr9⁺ PTCs was
237 significantly higher in Yaa mice at 24 wks of age compared to that in other examined
238 mice at both ages (Fig. 2I).

239 ***Expression of Tlr9 and its downstream cytokines in kidney tubulointerstitium***

240 As shown in Fig. 3, we examined mRNA expression in the tubulointerstitium by
241 using LMD following real-time PCR at 24 wks of age. mRNA expression of *Tlr9* was
242 significantly higher in Yaa mice than that in BXSB mice. Further, levels of its
243 downstream cytokines (28) including interleukin 1 beta (*Il1b*), *Il6*, interferon gamma
244 (*Ifng*), and tumor necrosis factor alpha (*Tnf*) also tended to be upregulated in the
245 tubulointerstitium of Yaa mouse kidneys compare to levels in BXSB mice, and significant
246 differences were observed for *Il1b* and *Il6*.

247 ***PTC injury in AGN model mice***

248 We examined ultrastructural injury of PTCs in all examined mouse kidneys.
249 mSEM showed that BXSB and Yaa mice at 8 wks of age exhibited preserved normal PTC
250 structures (Fig. 4A and B). BXSB mice at 24 wks of age showed normal PTCs but Yaa
251 mice at the same age showed PTC injury characterized by thickening of ECs, loss of
252 fenestration, and irregular capillary lumina (Fig. 4C and D). Yaa mice also showed wide
253 tubulointerstitial spaces, indicating edema, with infiltrating immune cells. For the
254 standard SEM method, BXSB mice at both ages and Yaa at 8 wks of age showed well-
255 preserved PTC lumina (Fig. 4E-G), but Yaa mice showed loss of endothelial fenestration
256 at 24 wks of age (Fig. 4H). A greater percentage of injured PTCs was found in Yaa mice
257 at 24 wks of age compared to other examined mice at both ages (Fig. 4I).

258

259 ***Tubular injury in AGN model mice***

260 In our previous study, increased numbers of IL-1F6/IL-36 α ⁺ distal tubules were
261 found in injured kidneys, which also related with TIL (27). Moreover, IL-1F6/IL-36 α ⁺
262 tubules were correlated with EC injury and PTC loss (5). BXSB and Yaa mice at 8 wks
263 of age showed no IL-1F6/IL-36 α ⁺ tubules (Fig. 5A and B). BXSB mice at 24 wks of age
264 showed normal tubules, but Yaa mice at the same age showed abundant IL-1F6/IL-36 α ⁺
265 tubules (Fig. 5C and D). Greater numbers of IL-1F6/IL-36 α ⁺ damaged tubules were found
266 in Yaa mice at 24 wks of age compared to those of 8 wks of Yaa mice and both ages of
267 BXSB mice (Fig. 5E). mSEM analysis also revealed tubular dilatation, flattened tubular
268 epithelium, wide tubulointerstitial spaces, and misshapen capillary lumina (Fig. 5F-I).
269 These data indicated that PTC injury was accompanied by tubular injury in Yaa mice at
270 24 wks of age.

271 ***Correlation among the indices of renal Tlr9 expression, PTC injuries, and TILs***

272 We analyzed the statistical correlation among renal *Tlr9* expression, PTC injuries,
273 and TILs by using the parameters obtained from all animals (Table 1). *Tlr9* expression
274 level in tubulointerstitium examined by LMD was positively and significantly correlated
275 with immune cell infiltration into TILs, mRNA expression of proinflammatory cytokines
276 (*Il1b*, *Tnf*) in the tubulointerstitium, the percentage of injured PTCs examined by mSEM,
277 and the number of IL-1F6/IL-36 α ⁺ tubules. The percentage of Tlr9⁺ PTCs and injured
278 PTCs examined by immunostaining and mSEM, respectively, also showed a similar

279 positive and significant tendency toward correlation, except for the parameters of
280 macrophage infiltration into TILs and mRNA expression of *Il6* and *Ifng* in
281 tubulointerstitium. The number of IL-1F6/IL-36 α ⁺ tubules was positively and
282 significantly correlated with immune cell infiltration into TILs, mRNA expression of
283 proinflammatory cytokines (except *Ifng*) in the tubulointerstitium, the percentage of
284 injured PTCs examined by mSEM, and the percentage of Tlr9⁺ PTCs.

285

286 **Discussion**

287 In the present study, we have introduced a potential role of the innate immune
288 system through activation of Tlr9 in PTC ECs in AGN model mice. We showed de novo
289 expression of Tlr9 in PTC ECs for the first time and subsequent injury. In addition, we
290 also elucidated the contribution of this injured PTC to the development of TILs in AGN.

291 Chronic GLs are thought to be converted into TILs by overfiltration of plasma
292 proteins, inflammatory cytokines, or hypoxia (29). Therefore, AGN can chronically
293 progress to ESRD through the interstitial fibrosis associated with the injury of renal
294 tubules and PTCs. Importantly, the number of damaged tubules increased with immune
295 cell infiltration and elevated expression of proinflammatory cytokines in the
296 tubulointerstitium of AGN model mice. In glomerulonephritis, resident glomerular cells
297 are damaged, and they secrete inflammatory cytokines that can activate interstitial cells
298 and induce inflammatory cell infiltration (30). Previously, we showed that injury and loss
299 of glomerular capillaries negatively correlated with the development of GLs. Importantly,
300 the efferent arterioles from the glomerulus allow the PTC to branch to the
301 tubulointerstitium. Further, as altered renal vasculature in the kidney leads to hypoxia
302 which results in renal inflammation in humans and experimental animals (6, 31), in the
303 present study, we attempted to determine the correlation between PTC injury and TILs in
304 AGN model mice. Importantly, the number of PTCs was not significantly altered in AGN
305 model mice, but the ultrastructural changes characterized by narrow and irregular of PTC
306 lumina, EC thickening with loss of fenestration, and EC activation or detachment with

307 peritubular infiltration of immune cells were clearly induced in PTCs in AGN model mice.
308 Furthermore, a significant positive correlation was found between PTC injury and TILs.
309 Therefore, we considered that PTC injury was accompanied with the development of
310 AGN and inflammatory TILs, and injured ECs of PTC in AGN caused local hypoxia
311 which can contribute to TIL development.

312 ECs are now considered active members of innate immunity that participate in the
313 innate immune response to infection and injury. Tlrs, members of the innate immune
314 response, are selectively expressed in ECs. Among Tlrs, *Tlr9* is expressed in different
315 ECs and causes tissue damage (20, 32). Moreover, our previous study showed that
316 overexpressing *Tlr8* and *Tlr9* in glomerular podocytes correlated with the progression of
317 AGN in mice (24, 25). Podocytes are crucial cells for maintaining the barrier between
318 renal tissues and the blood stream, known as the BUB. Similarly, renal tubular epithelial
319 cells and ECs of PTC have important roles in the barrier between renal tissues and the
320 bloodstream by reabsorbing filtrate components into the PTC and trafficking leukocytes
321 from the bloodstream to the extravascular space, respectively (33, 34). Therefore, similar
322 to podocytes, we hypothesized that tubulointerstitium like PTC ECs or tubular epithelium
323 would participate in the innate immune response by expressing Tlrs. As expected, in the
324 present study, we found that *Tlr9* mRNA was expressed in podocytes as well as ECs of
325 PTCs in Yaa mice. We also demonstrated that expression of *Tlr9* and its downstream
326 cytokines *Il1b*, *Il6*, *Ifng*, and *Tnf*, was induced by activation of the NF- κ B pathway (28)
327 in the tubulointerstitium of AGN mice. From these results, similar to the GL pathogenesis

328 via Tlr9-NF-kB (25), we concluded that this pathway also plays an important role in the
329 progression of TIL in AGN model mice.

330 *Tlr9* expression was observed only in AGN model mice at 24 wks of age, but not
331 in control and younger mice. The duplicated Yaa locus of Yaa mice contains
332 approximately 19 protein-coding genes including Tlr7 and Tlr8 (22, 23), whereas *Tlr9* is
333 located in the autosome. Further, this result was also confirmed by showing Tlr9 protein
334 localization in PTC of another AGN mouse model, the *lpr* strain. Therefore,
335 overexpression of *Tlr9* in PTC was not due to genomic factors, but systemic autoimmune
336 disease condition would increase its expression. Importantly, Tlr9 is localized to the
337 endosomes, and it can recognize internalized CpG-DNA from bacteria and DNA viruses
338 (35) and host-derived nucleic acids (36). Interestingly, immune-complexes containing
339 DNA internalized via Fc gamma receptor also seem to bind to Tlr9 in endosomes (37).
340 Importantly, the serum level of anti-dsDNA autoantibodies is remarkably high in Yaa
341 mice and *lpr* mice (25). Therefore, overexpression of *Tlr9* of ECs in PTCs might be
342 needed to process the increased immune-complexes circulating in the bloodstream and/or
343 reflected the increased endosomal activities in ECs. In fact, EC ultrastructural
344 observations showed increased cytoplasm size. Taken together, the results suggest that
345 Tlr9 participates in the progression of TILs as a modulator rather than an initiator by
346 activating downstream inflammatory pathways.

347 The activation of ECs through Tlrs was also found in humans and experimental
348 animals through prior inflammatory stimuli such as *Ifng*, *Tnf*, or *Ilb* (10, 32, 38). To

349 examine the response of ECs via Tlr9 by candidate ligands and/or cytokines, ex vivo
350 analysis of ECs in PTCs from the kidney would be useful. However, the expression of
351 Tlr family proteins depends on origin or location of ECs (34, 39). Although we isolated
352 glomeruli by bead-circulation methods and demonstrated faint *Tlr9* expression in
353 glomerular ECs with the combination of histological study (25), purifying the ECs in
354 PTCs would be unrealistic methodologically. Therefore, we applied the correlation
355 analysis between *Tlr9* expression and histopathological indices to estimate the function
356 of Tlr9 in ECs of PTCs. The present statistical analysis revealed that *Tlr9* expression in
357 tubulointerstitium was positively correlated with immune cell infiltration into TILs,
358 mRNA expression of proinflammatory cytokines (*Il1b*, *Tnf*) in the tubulointerstitium, the
359 percentage of injured PTCs examined by mSEM, and the number of IL-1F6/IL-36 α +
360 tubules. These results suggest that PTC ECs activation through Tlr9 induces
361 proinflammatory cytokine production, which enhances the injury of PTC ECs and tubules
362 in an autocrine and paracrine manner.

363 **Conclusion**

364 In summary, we have demonstrated that EC Tlr9 leads to inflammatory cell
365 recruitment into the tubulointerstitium and TILs in AGN. In addition, PTC injury and
366 TILs were accompanied by GLs in AGN model mice, suggesting crosstalk between the
367 glomerulus and tubulointerstitium during disease progression. However, critical details
368 about the postulated series of events remain to be elucidated, such as more specific
369 characterization of Tlr9 ligands that are induced in this model. The comparative

370 contribution of Tlr9 and other Tlrs would also be beneficial to elucidate a more complete
371 picture of the development of TILs in AGN.

372 **Funding**

373 This study was supported by a Grant-in-Aid for Scientific Research to a Graduate Student
374 from the Graduate School of Veterinary Medicine, Hokkaido University, Japan (Grant-in
375 Aid FY 2017, PH36150001, Mr. Masum) and Kazato Research Grants (Dr. Ichii).

376 **Acknowledgement**

377 The authors thank to Dr. David P. Basile (Indiana University School of Medicine, Indiana,
378 USA) for critical discussion and suggestions.

379 **Declaration of interest**

380 The authors declare that there were no competing of interests.

381 **References**

- 382 1. Nagata M, Ninomiya T, Doi Y, et al. Trends in the prevalence of chronic kidney
383 disease and its risk factors in a general Japanese population: the Hisayama
384 Study. *Nephrol Dial Transplant* 2010; 25: 2557–2564.
- 385 2. Kida Y, Tchoa BN and Yamaguchi I. Peritubular capillary rarefaction: a new
386 therapeutic target in chronic kidney disease. *Pediatr Nephrol* 2014; 29: 333–342.
- 387 3. Eddy AA. Molecular insights into renal interstitial fibrosis. *J Am Soc Nephrol*
388 1996; 7: 2495-2508.
- 389 4. Tonelli M, Wiebe N, Culeton B, et al. Chronic kidney disease and mortality risk: a
390 systematic review. *J Am Soc Nephrol* 2006; 17: 2034-2047.
- 391 5. Masum MA, Ichii O, Elewa YHA, Nakamura T and Kon Y. Local CD34-positive
392 capillaries decrease in mouse models of kidney disease associating with the severity
393 of glomerular and tubulointerstitial lesions. *BMC Nephrol* 2017; 18(1): 280. doi:
394 10.1186/s12882-017-0694-3.
- 395 6. Ohashi R, Kitamura H and Yamanaka N. Peritubular capillary injury during the
396 progression of experimental glomerulonephritis in rats. *J Am Soc Nephrol* 2000; 11:
397 47–56.
- 398 7. Panzer U, Steinmetz OM, Reinking RR, et al. Compartment-specific expression and
399 function of the chemokine IP-10/ CXCL10 in a model of renal endothelial
400 microvascular injury. *J Am Soc Nephrol* 2006; 17: 454–464.

- 401 8. Lim YC, Garcia-Cardena G, Allport JR, et al. Heterogeneity of endothelial cells from
402 different organ sites in T-cell subset recruitment. *Am J Pathol* 2003; 162: 1591–601.
- 403 9. Hickey MJ and Kubes P. Intravascular immunity: the host-pathogen encounter in
404 blood vessels. *Nat Rev Immunol* 2009; 9: 364-375.
- 405 10. Salvador B, Arranz A, Francisco S, et al. Modulation of endothelial function by Toll
406 like receptors. *Pharmacol Res* 2016; 108: 46-56.
- 407 11. Baccala R, Gonzalez-Quintial R, Lawson BR, et al. Sensors of the innate immune
408 system: their mode of action. *Nat Rev Rheumatol* 2009; 5: 448–456.
- 409 12. Garraud O and Cognasse F. Platelet Toll-like receptor expression: the link between
410 “danger” ligands and inflammation. *Inflamm Allergy Drug Targets* 2010; 9: 322–333.
- 411 13. Andersen-Nissen E, Hawn TR, Smith KD, et al. Cutting edge: Tlr5^{-/-} mice are more
412 susceptible to Escherichia coli urinary tract infection. *J Immunol* 2007; 178: 4717–
413 4720.
- 414 14. Zhang D, Zhang G, Hayden MS, et al. A toll-like receptor that prevents infection by
415 uropathogenic bacteria. *Science* 2004; 303: 1522–1526.
- 416 15. Shigeoka AA, Holscher TD, King AJ, et al. TLR2 is constitutively expressed within
417 the kidney and participates in ischemic renal injury through both MyD88-dependent
418 and-independent pathways. *J Immunol* 2007; 178: 6252–6258.
- 419 16. Papadimitraki ED, Tzardi M, Bertias G, Sotsiou E and Boumpas DT. Glomerular
420 expression of toll-like receptor-9 in lupus nephritis but not in normal kidneys:
421 implications for the amplification of the inflammatory response. *Lupus* 2009; 18:
422 831–835.

- 423 17. Machida H, Ito S, Hirose T, et al. Expression of Toll-like receptor 9 in renal
424 podocytes in childhood-onset active and inactive lupus nephritis. *Nephrol Dial*
425 *Transplant* 2010; 25: 2530–2537.
- 426 18. Anders HJ, Banas B, Linde Y, et al. Bacterial CpG-DNA aggravates
427 glomerulonephritis: role of TLR9-mediated expression of chemokines and
428 chemokine Receptors. *J Am Soc Nephrol* 2003; 14: 317–326.
- 429 19. Li J, Ma Z, Tang ZL, et al. CpG DNA-mediated immune response in pulmonary
430 endothelial cells. *Am J Physiol* 2004; 287: L552–L558.
- 431 20. Martin-Armas M, Simon-Santamaria J, Pettersen I, et al. Toll-like receptor 9 (TLR9)
432 is present in murine liver sinusoidal endothelial cells (LSEC) and mediates the effect
433 of CpG-oligonucleotides. *J Hepatol* 2006; 44: 939–946.
- 434 21. Fitzner N, Clauberg S, Essmann F, et al. Human skin endothelial cells can express
435 all 10 TLR genes and respond to respective ligands. *Clin Vaccine Immunol* 2008, 15:
436 138–146.
- 437 22. Santiago-Raber ML, Laporte C, Reininger L, Izui S. Genetic basis of murine lupus.
438 *Autoimmun Rev* 2004; 3: 33–39.
- 439 23. Subramanian S, Tus K, Li QZ, et al. A Tlr7 translocation accelerates systemic
440 autoimmunity in murine lupus. *Proc Natl Acad Sci USA* 2006; 103: 9970–9975.
- 441 24. Kimura J, Ichii O, Miyazono K, et al. Overexpression of toll-like receptor 8
442 correlates with the progression of podocyte injury in murine autoimmune
443 glomerulonephritis. *Sci Rep* 2014; 4: 7290. doi: 10.1038/srep07290.

- 444 25. Masum MA, Ichii O, Elewa YHA, et al. Overexpression of Toll-like receptor 9
445 correlates with podocyte injury in a murine model of autoimmune
446 membranoproliferative glomerulonephritis. *Autoimmunity* (Submitted, under
447 revision).
- 448 26. Masum MA, Ichii O, Elewa YHA, et al. Modified scanning electron microscopy
449 reveals pathological crosstalk between endothelial cells and podocytes in a murine
450 model of membranoproliferative glomerulonephritis. *Sci Rep* 2018; 8: 10276. doi:
451 10.1038/s41598-018-28617-1.
- 452 27. Ichii O, Otsuka S, Sasaki N, et al. Local overexpression of interleukin-1 family,
453 member 6 relates to the development of tubulointerstitial lesions. *Lab Invest* 2010;
454 90: 459–475.
- 455 28. Shirali AC and Goldstein DR. Tracking the Toll of Kidney Disease. *J Am Soc*
456 *Nephrol* 2008; 19: 1444–1450.
- 457 29. Kriz W and LeHir M. Pathways to nephron loss starting from glomerular diseases:
458 insights from animal models. *Kidney Int* 2005; 67: 404–419.
- 459 30. Pichler R, Giachelli C, Young B, et al. The pathogenesis of tubulointerstitial disease
460 associated with glomerulonephritis: The glomerular cytokine theory. *Miner*
461 *Electrolyte Metab* 1995; 21: 317–327.
- 462 31. Fine LG and Norman JT. Chronic hypoxia as a mechanism of progression of chronic
463 kidney diseases: from hypothesis to novel therapeutics. *Kidney Int* 2008; 74: 867–
464 872.

- 465 32. El Kebir D, Jozsef L, Pan W, Wang L and Filep JG. Bacterial DNA Activates
466 Endothelial cells and promotes neutrophil adherence through TLR9 signaling. *J*
467 *Immunol* 2009; 182: 4386–4394.
- 468 33. Vedula M, Alonso JL, Arnaout MA and Charest JL. A microfluidic renal proximal
469 tubule with active reabsorptive function. *PLoS ONE* 2017; 12: e0184330.
470 <https://doi.org/10.1371/journal.pone.0184330>.
- 471 34. Khakpour S, Wilhelmsen K and Hellman J. Vascular endothelial cell toll-like
472 receptor pathways in sepsis. *Innate Immun* 2015; 21: 827–846.
- 473 35. Hemmi H, Takeuchi O, Kawai T, et al S. A Toll-like receptor recognizes bacterial
474 DNA. *Nature* 2000; 408: 740–745
- 475 36. Saitoh S and Miyake K. Regulatory molecules required for nucleotide sensing Toll-
476 like receptors. *Immunol Rev* 2009; 227: 32–43.
- 477 37. Means TK, Latz E, Hayashi F, et al. Human lupus autoantibody-DNA complexes
478 activate DCs through cooperation of CD32 and TLR9. *J Clin Invest* 2005; 115: 404-
479 417.
- 480 38. Sabry A, Sheashaa H, El-Husseini A, et al. Proinflammatory cytokines (Tnfalpha and
481 IL-6) in Egyptian patients with SLE: its correlation with disease activity. *Cytokine*
482 2006; 35: 148–153

483 39. Opitz B, Eitel J, Meixenberger K and Suttorp N. Role of toll-like receptors, NOD-
484 like receptors and RIG-I-like receptors in endothelial cells and systemic infections.
485 *Thromb Haemost* 2009; 102: 1103–1109.
486

487 **Figure 1. GLs and TILs in AGN model mice**

488 (A-D) GLs and TILs in PAS-H stained sections obtained from BXSB and Yaa mice at 8
489 and 24 wks of age. BXSB mice show no lesions at 8 and 24 wks of age (A and C). Yaa
490 mice show no lesions at 8 wks of age (B) but exhibited GLs at 24 wks (dashed area), and
491 TILs characterized by dilated tubules (arrow) containing urinary cast (arrowhead) (D).
492 Bars = 100 μ m.

493 (E and F) Number of infiltrating cells in kidneys from AGN model mice. Number of
494 infiltrating B-, T-cells, and macrophages in glomerulus (E) and tubulointerstitium (F) of
495 BXSB and Yaa mice at 8 and 24 wks of age. Values are mean \pm s.e. *: Significant
496 difference from the control in the same disease group, Mann-Whitney U test (* $p < 0.05$).
497 # Significant difference from the other groups, Kruskal-Wallis test followed by Scheffe's
498 method (## $p < 0.01$). n = 4. GLs: Glomerular lesions, TILs: Tubulointerstitial lesions,
499 AGN: autoimmune glomerulonephritis, PAS-H: periodic acid Schiff-hematoxylin,
500 BXSB: BXSB/MpJ, Yaa: BXSB/MpJ-Yaa, wks: weeks and ND: not detected.

501

502 **Figure 2. Expression and localization of Tlr9 in tubulointerstitium of AGN model**
503 **mice**

504 (A and B) In situ expression of Tlr9 mRNA in the tubulointerstitium of BXSB and Yaa
505 mice at 8 wks of age as determined by in situ hybridization. There are no signals in the
506 tubulointerstitium of BXSB (A) or Yaa mice (B) at 8 wks of age.

507 (C and D) In situ expression of Tlr9 mRNA in the tubulointerstitium of BXSB and Yaa
508 mice at 24 wks of age as determined by in situ hybridization. There are a scant number
509 of signals for the genes hybridized with the probe for Tlr9 mRNA in the PTC of control
510 BXSB mice at 24 wks of age (C). There are numerous strong signals (arrows) for the
511 genes hybridized with the probe for Tlr9 mRNA in the PTC of model mice (Yaa) at 24
512 wks of age (D). Bars = 50 μ m.

513 (E and F) Tlr9 protein localization in the tubulointerstitium of BXSB and Yaa mice at 8
514 wks of age as determined by immunofluorescence. There is no immunoexpression in the
515 tubulointerstitium of BXSB (E) or Yaa mice (F) at 8 wks of age.

516 (G and H) Tlr9 protein localization in the tubulointerstitium of BXSB and Yaa mice at
517 24 wks of age as determined by immunofluorescence. There is no Tlr9 protein
518 localization in the PTC of control BXSB mice at 24 wks of age (G). Tlr9 protein localized
519 in the PTC of model mice (Yaa) at the same age (H). Bars = 50 μ m.

520 (I) Percentage of PTC showing Tlr9 protein localization in BXSB and Yaa mice at 8 and
521 24 wks of age. Values are mean \pm s.e. *: Significant difference from the control in the
522 same disease group, Mann-Whitney U test (**p < 0.01). # Significant difference from the
523 other groups, Kruskal-Wallis test followed by Scheffe's method (##p < 0.01). n = 4.
524 AGN: autoimmune glomerulonephritis, PTC: peritubular capillary, BXSB: BXSB/MpJ,
525 Yaa: BXSB/MpJ-Yaa, wks: weeks, and ND: not detected.

526

527 **Figure 3. Expression of *Tlr9* and its downstream factors in the tubulointerstitium of**
528 **in AGN model mice**

529 Relative mRNA expression of *Tlr9* and its downstream factors, including *Ilb*, *Il6*, *Ifng*,
530 and *Tnf* in the tubulointerstitium isolated from BXSB and Yaa mice at 24 weeks of age;
531 analysis was conducted by real-time PCR. The expression levels were normalized to the
532 levels of *Actb*. Values are mean \pm s.e. *Significantly different from BXSB mice at the
533 same age (Mann-Whitney *U*-test, $P < 0.05$); n = 4. *Il1b*: interleukin 1 beta, *Il6*: interleukin
534 6, *Ifng*: interferon gamma, *Tnf*: tumor necrosis factor alpha, AGN: autoimmune
535 glomerulonephritis, BXSB: BXSB/MpJ, Yaa: BXSB/MpJ-*Yaa*, and wks: weeks.

536 **Figure 4. PTC injury in AGN model mice**

537 **(A-D)** PTC injury in BXSB and Yaa mice at 8 and 24 wks of age as determined by mSEM.
538 Normal PTC in BXSB mice at 8 and 24 wks of age (A and C). Yaa mice show normal
539 PTC at 8 wks of age (B) but show thickening of endothelial cytoplasm with loss of
540 fenestration at 24 wks (D). Bars = 5 μ m.

541 **(E-H)** Morphological changes of PTC lumen in BXSB and Yaa mice at 8 and 24 wks of
542 age as determined by SEM. BXSB mice show normal PTC lumen at 8 and 24 wks of age
543 (E and G). Yaa mice also show normal PTC lumen at 8 wks of age (F) but show loss of
544 endothelial fenestration at 24 wks (H). Bars = 5 μ m.

545 **(I)** Percentage of injured PTCs in BXSB and Yaa mice at 8 and 24 wks of age. Values
546 are mean \pm s.e. *: Significant difference from the control in the same disease group, Mann-

547 Whitney *U* test (***p* < 0.01). # Significant difference from the other groups, Kruskal-
548 Wallis test followed by Scheffe's method (###*p* < 0.01). *n* = 4. mSEM: Modified scanning
549 electron microscopy, SEM: Scanning electron microscopy, AGN: autoimmune
550 glomerulonephritis, PTC: peritubular capillary, BXSB: BXSB/MpJ, Yaa: BXSB/MpJ-
551 *Yaa*, wks: weeks and ND: not detected.

552

553 **Figure 5. TILs in AGN model mice**

554 (A-D) IL-1F6/IL-36 α + damaged tubules in tubulointerstitium of BXSB and Yaa mice at
555 8 and 24 wks of age as determined by immunohistochemistry. BXSB mice show no
556 tubular injury at 8 and 24 wks of age (A and C). Yaa mice show no tubular injury at 8
557 wks of age (B) but show many IL-1F6/IL-36 α + damaged tubules in the tubulointerstitium
558 at 24 wks (arrow) (D). Bars = 100 μ m.

559 (E) Number of IL-1F6/IL-36 α + damaged tubules in the tubulointerstitium of BXSB and
560 Yaa mice at 8 and 24 wks of age. Values are mean \pm s.e. *: Significant difference from
561 the control in the same disease group, Mann-Whitney *U* test (***p* < 0.01). # Significant
562 difference from the other groups, Kruskal-Wallis test followed by Scheffe's method (###*p*
563 < 0.01).

564 (F-I) TILs in BXSB and Yaa mice at 8 and 24 wks of age as determined by mSEM. BXSB
565 mice show normal tubulointerstitium at 8 and 24 wks of age (F and H). Yaa also show
566 normal tubulointerstitium at 8 wks of age (G) but show dilated tubules (arrow), edematous

567 tubulointerstitial space (arrowhead), and narrow PTC (empty arrowhead) at 24 wks (I).
568 Bars = 10 μ m. TILs: Tubulointerstitial lesions, mSEM: Modified scanning electron
569 microscopy, AGN: autoimmune glomerulonephritis, PTC: peritubular capillary, BXSB:
570 BXSB/MpJ, Yaa: BXSB/MpJ-Yaa, wks: weeks, and ND: not detected.

Figure 1






Figure 2





Figure 3




Figure 4







Figure 5





Supplementary Figure 1. Distribution of PTC in AGN model mice


(A and B) Distribution of CD31⁺ PTCs in BXSB and Yaa mice at 24 wks of age, as shown by immunofluorescence. Normal distribution of CD31⁺ PTC (arrows) in BXSB (A) and Yaa (B) mice kidney at 24 wks of age. Bars = 100μm.

(C) Number of CD31⁺ PTCs in BXSB and Yaa mice kidneys at 24 wks of age. Values are mean ± s.e. Mann-Whitney *U*-test, n = 4.

(D and E) Distribution of PTC in Microfil-perfused thick kidney sections obtained from BXSB and Yaa mice at 24 wks of age. Normal distribution of PTC (arrows) in BXSB (D) and Yaa (E) mice kidneys.

AGN: autoimmune glomerulonephritis, PTC: peritubular capillary, BXSB: BXSB/MpJ, Yaa: BXSB/MpJ-Yaa, and wks: weeks.


Supplementary Figure 2



Supplementary Figure 2. *Tlr9* expression and localization in glomerulus of AGN model mice.

Tlr9 expression (black arrow) in glomerulus of BXSB (A) and Yaa (B) mice at 24 weeks of age. *Tr9* protein localization (arrow) in the glomerulus of BXSB (C) and Yaa (D) mice at 24 weeks of age. Bars=50 μ m. AGN: autoimmune glomerulonephritis, BXSB: BXSB/MpJ and Yaa: BXSB/MpJ-*Yaa*

Supplementary Figure 3



Supplementary Figure 3. Localization of Tlr9 in PTC and spleen.

Tlr9 protein localization (arrow) in the PTC of MRL/MpJ (A) and MRL/MpJ-*lpr* (B) mice at 24 weeks of age. Positive immunoreaction (arrow) also examined in spleen of Yaa mice at 24 weeks of age (C). Bars=100 μ m. MRL: MRL/MpJ, *lpr*: MRL/Mp-*lpr* and Yaa: BXSJ/MpJ-*Yaa*.